MAKERSL177.20

Makers Laboratories Limited

· Pharma & Health
₹ CrorePeersBPLPHARMAJENBURPHKPLNOVARTINDPARNAXLABSGRLSHUKRAPHARSUNLOC
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Returns
Return on Common Equity-13.51-3.16
Return on Assets-8.07-2.34
Return on Invested Capital-9.96-6.73-3.10
Margins
EBITDA Margin-7.66-5.141.45
Operating Margin-13.19-11.77-4.12
Incremental Operating Margin-23.1340.28
Pretax Margin-14.1711.48-3.99
Net Income Margin-14.16-3.42
FCF Margin-11.73-9.34-4.63
Additional
Effective Tax Rate0.0614.49
Sustainable Growth Rate-13.51-3.16
Incremental Operating Margin %-23.1340.28
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 85%.